Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCCC 2236 artesunate vaginal suppository study in cervical intraepithelial neoplasia
PACTR202312740571041Phase 1Not yet recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of artesunate in cervical intraepithelial neoplasia (CIN), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Safety. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
artesunate
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on PACTR202312740571041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202312740571041.